Table 1 Patients’ characteristics, including indication for HSCT, donor, conditioning regimen and GvHD prophylaxis are summarized in the table.
Patient code | Indication HSCT | Recipient sex | Donor sex | Donor type | HSC Source | Conditioning regimen | GvHD prophylaxis | Rituximab | Months post-HSCT |
|---|---|---|---|---|---|---|---|---|---|
1 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | yes | 3,4,5 |
2 | Beta-thal. | M | F | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | no | 2,3,4 |
3 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | yes | 4,5,6,7,10 |
4 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | yes | 15.16 |
5 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | yes | 7,8,12 |
6 | ALL | M | F | MMD | BM | TBI + VP16 | Csa, MMF, PTCy | no | 2.4 |
7 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | no | 38 |
8 | MPS-1 | M | F | MUD 10/10 | BM | Treo + Flu + TT | Csa, mPDN, ATLG | yes | 8 |
9 | Beta-thal. | M | F | MUD 10/10 | BM | Treo + Flu + TT | Csa, MTX, ATLG | yes | 58 |
10 | SCD | F | M | MSD | BM | Treo + Flu + TT | Csa, MTX, ATLG | no | 1 |
